Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors (NCT05040360)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 120 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam
2. Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report
3. Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be \>= 3% and =\< 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and/or the study pathology chair with questions. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria
4. Participants with localized resected pNETS must have a Zaidi score of \>= 3 derived by the following factors and points:
5. 1 point; symptomatic tumor defined as one of the following:
6. Gastrointestinal bleed
7. Jaundice
8. Gastrointestinal obstruction
9. Pain from primary tumor prior to surgical resection
10. Pancreatitis
11. 2 points; primary pancreas tumor size \> 2 cm
12. 1 point; Ki-67 3% to 20%

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (448 Sites)

• Anchorage Associates in Radiation Medicine — Anchorage, Alaska
• Anchorage Radiation Therapy Center — Anchorage, Alaska
• Alaska Breast Care and Surgery LLC — Anchorage, Alaska
• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Alaska Women's Cancer Care — Anchorage, Alaska
• Anchorage Oncology Centre — Anchorage, Alaska
• Katmai Oncology Group — Anchorage, Alaska
• Providence Alaska Medical Center — Anchorage, Alaska
• Fairbanks Memorial Hospital — Fairbanks, Alaska
• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Kingman Regional Medical Center — Kingman, Arizona
• Cancer Center at Saint Joseph's — Phoenix, Arizona
• Mayo Clinic Hospital in Arizona — Phoenix, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• Mercy Hospital Fort Smith — Fort Smith, Arkansas
• CARTI Cancer Center — Little Rock, Arkansas
• Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
• PCR Oncology — Arroyo Grande, California
• Tower Cancer Research Foundation — Beverly Hills, California
• Keck Medicine of USC Buena Park — Buena Park, California
• Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
• Mercy Cancer Center - Carmichael — Carmichael, California
• Mercy San Juan Medical Center — Carmichael, California
• Epic Care-Dublin — Dublin, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.